A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04657302 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: Obinutuzumab
DRUG: Glofitamab
DRUG: Tocilizumab

Sponsor

Hoffmann-La Roche